TCL Archive Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials September 26, 2014
TCL Archive NCAB Cancer Centers committee recommends Ratio Cap To Limit Growth of Largest Grants February 14, 1992